Protective vaccines have been developed, but current supplies are too low to cover global demand in the coming months.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to grow, with >550 000 new infections and >9000 deaths recorded worldwide daily in July 2021. A network of large clinical trials is in progress to validate the results seen to date.ĬOVID-19, ivermectin, repurposed, SARS-CoV-2 Currently, the World Health Organization recommends the use of ivermectin only inside clinical trials. There was no significant effect of ivermectin on time to clinical recovery (mean difference, –0.57 days 95% CI, –1.31 to 0.17 P =. Ivermectin displayed a borderline significant effect on duration of hospitalization in comparison with standard of care (mean difference, –1.14 days 95% CI, –2.27 to –0.00 P =. Ivermectin did not show a statistically significant effect on survival (risk ratio, 0.90 95% CI, 0.57 to 1.42 P =. The primary meta-analysis was carried out by excluding studies at a high risk of bias.
Comprehensive meta analysis version 3 trial#
This meta-analysis investigated ivermectin in 23 randomized clinical trials (3349 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries. Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations.
Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
0 kommentar(er)
